Marche

Abstract

In Marche region 65,7% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 26 cases of cervicocarcinoma and 11 related deaths and thus results to be cost-effective (21.677 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 25 cancer cases and 11 deaths could be prevented, with a very similar cost-effectiveness ratio. In Marche region, the net cost for woman vaccinated is 155 € for the single cohort and 158 € for the multiple cohort.

Keywords

• marche
• hpv vaccination
• economic & clinical impact